AMRX - Amneal Pharmaceuticals Inc Stock Price, Fair Value and News

5.45USD-0.09 (-1.62%)Market Closed

Market Summary

USD5.45-0.09

Market Closed

-1.62%

AMRX Stock Price

View Fullscreen

AMRX RSI Chart

AMRX Valuation

Market Cap

835.8M

Price/Earnings (Trailing)

-10.54

Price/Sales (Trailing)

0.35

EV/EBITDA

21.49

Price/Free Cashflow

2.76

AMRX Price/Sales (Trailing)

AMRX Profitability

EBT Margin

-1.68%

Return on Equity

-396.11%

Return on Assets

-2.28%

Free Cashflow Yield

36.18%

AMRX Fundamentals

AMRX Revenue

Revenue (TTM)

2.4B

Rev. Growth (Yr)

1.18%

Rev. Growth (Qtr)

-0.49%

AMRX Earnings

Earnings (TTM)

-79.3M

Earnings Growth (Yr)

-743.22%

Earnings Growth (Qtr)

-752.55%

Breaking Down AMRX Revenue

Last 7 days

-4.9%

Last 30 days

-0.9%

Last 90 days

4.0%

Trailing 12 Months

230.3%

How does AMRX drawdown profile look like?

AMRX Financial Health

Current Ratio

1.63

Debt/Equity

127.02

Debt/Cashflow

0.14

AMRX Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

-0.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.3B	2.3B	2.4B	2.4B
2022	2.1B	2.1B	2.1B	2.2B
2021	2.0B	2.1B	2.1B	2.1B
2020	1.7B	1.7B	1.9B	2.0B
2019	1.8B	1.8B	1.7B	1.6B
2018	1.1B	1.2B	1.5B	1.7B
2017	1.0B	1.0B	1.0B	1.0B
2016	0	0	0	1.0B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amneal Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	konidaris tasos	sold (taxes)	-163,495	5.31	-30,790	executive vice president & cfo
Mar 12, 2024	konidaris tasos	acquired	-	-	87,720	executive vice president & cfo
Mar 03, 2024	shah nikita	sold (taxes)	-225,008	5.47	-41,135	executive vice president
Mar 03, 2024	konidaris tasos	sold (taxes)	-197,046	5.47	-36,023	executive vice president & cfo
Mar 03, 2024	boyer andrew s	sold (taxes)	-243,754	5.47	-44,562	executive vice president
Mar 03, 2024	boyer andrew s	acquired	-	-	88,945	executive vice president
Mar 03, 2024	daly jason b.	acquired	-	-	60,871	svp, chief legal officer
Mar 03, 2024	shah nikita	acquired	-	-	82,103	executive vice president
Mar 03, 2024	daly jason b.	sold (taxes)	-98,624	5.47	-18,030	svp, chief legal officer
Mar 03, 2024	konidaris tasos	acquired	-	-	102,629	executive vice president & cfo

Which funds bought or sold AMRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 11, 2024	SANDERS MORRIS HARRIS LLC	new	-	1,512,550	1,512,550	0.28%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	-10.00	5,854	-%
Apr 09, 2024	Rise Advisors, LLC	unchanged	-	-5.00	3,030	-%
Apr 05, 2024	CWM, LLC	added	54.9	6,000	18,000	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	170	170	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	72.93	835	1,396	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.69	25,635,500	82,809,300	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-39.5	-610,632	4,094,470	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	111,061	367,793	-%
Feb 16, 2024	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	reduced	-28.27	4,588	164,588	-%

Are Funds Buying or Selling AMRX?

Are funds buying AMRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMRX

No. of Funds

Unveiling Amneal Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.45%	13,642,387	SC 13G/A
Jan 05, 2024	mahesh akram	9.%	30,384,769	SC 13G
Jan 03, 2024	patel gautam	0.07%	2,025,454	SC 13D/A
Dec 12, 2023	fosun international ltd	5.4%	16,438,356	SC 13G/A
Dec 01, 2023	patel gautam	11.1%	33,885,406	SC 13D/A
Nov 08, 2023	patel gautam	10.0%	30,812,108	SC 13D/A
Nov 08, 2023	patel tushar bhikhubhai	17.5%	53,578,209	SC 13D/A
Nov 08, 2023	patel chintu	8.3%	25,318,839	SC 13D/A
Nov 08, 2023	patel dipan	8.8%	26,905,073	SC 13D/A
Nov 08, 2023	patel chirag k.	7.1%	21,835,007	SC 13D/A

Recent SEC filings of Amneal Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Mar 22, 2024	DEFA14A	DEFA14A
Mar 22, 2024	DEF 14A	DEF 14A
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	10-K	Annual Report
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Amneal Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	348.0B	85.2B	-8.67%	-12.80%	9.9	4.09	6.46%	95.94%
MRK	316.7B	60.1B	2.91%	8.74%	867.76	5.27	1.40%	-97.49%
PFE	145.1B	46.5B	-8.05%	-37.62%	-104.48	3.12	42.59%	-114.62%
AMGN	142.4B	28.2B	-1.17%	7.12%	21.2	5.05	7.09%	2.52%
GILD	83.9B	27.1B	-8.64%	-19.50%	14.81	3.09	-0.60%	23.36%
TEVA	14.7B	15.8B	-2.46%	54.12%	-25.47	0.93	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-1.38%	-18.66%	-319.58	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-17.22%	-19.16%	11.18	2.39	49.61%	324.78%
BHC	3.2B	8.8B	-5.00%	14.25%	-5.39	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-4.97%	-2.50%	14.31	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	6.36%	-26.40%	-4.05	1.92	24.65%	80.36%
TXMD	22.1M	1.3M	-20.00%	-47.68%	-2.15	0.38	-98.14%	-109.18%
ACRX	17.3M	-	-11.30%	34.21%	-0.94	0.22	2882.68%	-138.52%
AGRX	1.2M	19.6M	-27.78%	-94.56%	-0.08	0.06	80.00%	43.08%
ACOR	496.8K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Amneal Pharmaceuticals Inc News

Latest updates

Amneal Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-0.5%	617	620	599	558	610	546	559	498	537	529	535	493	510	519	465	499	397	378	405	446	498
Gross Profit	-18.4%	190	233	220	178	215	194	201	175	166	199	212	192	167	134	144	183	110	54.00	105	83.00	193
S&GA Expenses	-3.5%	109	113	106	102	102	100	99.00	99.00	97.00	91.00	86.00	91.00	85.00	83.00	81.00	78.00	74.00	64.00	67.00	84.00	71.00
R&D Expenses	11.4%	46.00	41.00	38.00	39.00	42.00	50.00	51.00	53.00	52.00	49.00	53.00	48.00	53.00	45.00	46.00	36.00	48.00	38.00	48.00	54.00	57.00
EBITDA Margin	-31.7%	0.06*	0.09*	0.08*	-0.04*	-0.05*	-0.06*	-0.07*	0.06*	0.07*	0.08*	0.07*	0.05*	0.05*	0.03*	0.06*	0.05*	-0.04*	-0.01*	-0.01*	-0.13*	-0.04*
Interest Expenses	17.4%	56.00	48.00	48.00	41.00	51.00	35.00	30.00	27.00	30.00	30.00	32.00	30.00	31.00	31.00	33.00	35.00	37.00	41.00	41.00	40.00	42.00
Income Taxes	577.1%	10.00	-2.08	-	1.00	-1.80	5.00	7.00	-3.50	4.00	4.00	3.00	0.00	2.00	0.00	2.00	-108	7.00	390	-5.70	-8.43	6.00
Earnings Before Taxes	-463.6%	-83.46	23.00	30.00	-9.43	-7.65	2.00	-232	-9.92	-16.32	-2.04	35.00	15.00	-5.48	-21.89	-21.76	13.00	-57.11	26.00	-56.23	-133	-14.81
EBT Margin	-213.0%	-0.02*	0.01*	0.01*	-0.11*	-0.11*	-0.12*	-0.12*	0.00*	0.01*	0.02*	0.01*	-0.02*	-0.02*	-0.05*	-0.02*	-0.04*	-0.14*	-0.10*	-0.10*	-0.21*	-0.12*
Net Income	-752.5%	-101	16.00	22.00	-15.63	-12.03	-7.61	-242	-8.82	-21.80	-7.78	30.00	13.00	-6.83	-21.64	-24.16	120	-64.90	-265	-16.90	-47.88	-20.33
Net Income Margin	-881.2%	-0.03*	0.00*	-0.01*	-0.12*	-0.12*	-0.13*	-0.13*	0.00*	0.01*	0.01*	0.01*	-0.02*	0.03*	0.01*	-0.13*	-0.13*	-0.24*	-0.20*	-0.04*	-0.16*	-0.24*
Free Cashflow	80.6%	126	70.00	-23.35	130	-34.76	74.00	-130	110	46.00	72.00	-59.74	136	76.00	34.00	171	42.00	-55.41	127	9.00	-126	240

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.8%	3,473	3,687	3,701	3,627	3,799	3,874	4,041	3,889	3,940	3,974	4,023	3,960	4,006	4,038	4,057	4,391	3,666	3,704	4,262	4,385	4,353
Current Assets	-5.4%	1,378	1,456	1,422	1,307	1,412	1,420	1,554	1,390	1,520	1,570	1,563	1,560	1,552	1,544	1,481	1,774	1,210	1,206	1,186	1,268	1,287
Cash Equivalents	5.3%	92.00	87.00	109	145	26.00	87.00	92.00	210	248	303	278	452	347	281	266	405	153	213	55.00	64.00	219
Inventory	0.9%	581	576	551	529	531	544	533	512	489	520	523	497	491	476	444	438	381	402	415	448	457
Net PPE	-0.9%	448	452	459	463	470	470	484	501	514	460	468	471	478	462	461	468	478	491	508	514	544
Goodwill	0.0%	599	599	599	599	599	600	601	603	593	566	549	44.00	523	523	527	515	420	420	420	422	426
Current Liabilities	11.3%	847	761	777	704	753	818	993	602	677	667	673	637	677	668	655	965	550	535	546	600	554
Long Term Debt	-6.1%	2,386	2,542	2,549	2,562	2,592	2,607	2,622	2,673	2,680	2,688	2,720	2,728	2,735	2,757	2,765	2,772	2,609	2,614	2,620	2,625	2,631
LT Debt, Current	11.8%	34.00	31.00	30.00	30.00	30.00	30.00	30.00	31.00	31.00	30.00	30.00	30.00	44.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-6.1%	2,386	2,542	2,549	2,562	2,592	2,607	2,622	2,673	2,680	2,688	2,720	2,728	2,735	2,757	2,765	2,772	2,609	2,614	2,620	2,625	2,631
Shareholder's Equity	-94.0%	20.00	331	151	135	298	194	173	407	367	383	390	367	345	348	371	403	347	396	749	800	896
Retained Earnings	-25.2%	-490	-391	-401	-413	-406	-401	-399	-278	-276	-269	-265	-280	-286	-283	-274	-262	-377	-345	-80.75	-63.84	-20.92
Additional Paid-In Capital	-24.6%	539	715	708	701	692	684	676	667	658	651	643	634	628	623	618	612	607	566	544	537	530
Shares Outstanding	14.8%	176	153	153	152	151	151	151	150	149	149	149	148	147	148	147	147	132	129	128	128	127
Minority Interest	100.1%	0.00	-176	-167	-159	-114	-103	-107	16.00	7.00	33.00	44.00	44.00	42.00	47.00	65.00	85.00	115	178	290	328	392
Float	-	-	-	464	-	-	-	471	-	-	-	751	-	-	-	696	-	-	-	1,202	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	66.9%	136	81.00	-11.34	140	-23.29	94.00	-125	120	63.00	82.00	-51.93	148	106	45.00	179	49.00	-50.89	140	21.00	-108	260
Share Based Compensation	-10.7%	6.00	7.00	7.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	5.00	5.00	5.00	6.00	5.00	5.00	6.00	6.00	4.00	4.00
Cashflow From Investing	-135.2%	-31.69	-13.48	-12.28	-11.74	-11.47	-49.33	-16.12	-97.39	-86.97	-11.63	-82.89	-12.69	-31.79	-14.78	-8.93	-262	-4.77	30.00	-23.33	-21.47	5.00
Cashflow From Financing	-16.5%	-100	-86.58	-12.26	-12.90	-22.17	-46.13	23.00	-61.57	-30.35	-43.55	-38.07	-26.15	-11.28	-14.81	-310	468	-7.30	-7.60	-9.07	-21.86	-218
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00

AMRX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenue	$ 2,393,607	$ 2,212,304	$ 2,093,669
Cost of goods sold	1,573,042	1,427,596	1,324,696
Gross profit	820,565	784,708	768,973
Selling, general and administrative	429,675	399,700	365,504
Research and development	163,950	195,688	201,847
In-process research and development impairment charges	30,800	12,970	710
Intellectual property legal development expenses	3,828	4,358	7,716
Acquisition, transaction-related and integration expenses	0	709	8,055
Restructuring and other charges	1,749	1,421	1,857
Change in fair value of contingent consideration	(14,497)	731	200
(Insurance recoveries) charges for property losses and associated expenses, net	0	(1,911)	5,368
Charges related to legal matters, net	1,824	269,930	25,000
Other operating income	(1,138)	(3,960)	0
Operating income (loss)	204,374	(94,928)	152,716
Other (expense) income:
Interest expense, net	(210,629)	(158,377)	(136,325)
Foreign exchange gain (loss), net	1,671	(12,364)	(355)
Loss on refinancing	(40,805)	(291)	0
Other income, net	5,119	17,833	15,330
Total other expense, net	(244,644)	(153,199)	(121,350)
(Loss) income before income taxes	(40,270)	(248,127)	31,366
Provision for income taxes	8,452	6,662	11,196
Net (loss) income	(48,722)	(254,789)	20,170
Less: Net (income) loss attributable to non-controlling interests	(35,271)	125,241	(9,546)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest	(83,993)	(129,548)	10,624
Accretion of redeemable non-controlling interest	0	(438)	0
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	$ (83,993)	$ (129,986)	$ 10,624
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
Basic (in dollars per share)	$ (0.48)	$ (0.86)	$ 0.07
Diluted (in dollars per share)	$ (0.48)	$ (0.86)	$ 0.07
Weighted-average common shares outstanding:
Basic (in shares)	176,136	150,944	148,922
Diluted (in shares)	176,136	150,944	151,821

AMRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 91,542	$ 25,976
Restricted cash	7,565	9,251
Inventories	581,384	530,735
Prepaid expenses and other current assets	82,685	103,565
Total current assets	1,377,863	1,411,818
Property, plant and equipment, net	447,574	469,815
Goodwill	598,629	598,853
Intangible assets, net	890,423	1,096,093
Operating lease right-of-use assets	43,283	56,121
Other assets	55,517	103,217
Total assets	3,472,569	3,799,341
Current liabilities:
Current portion of liabilities for legal matters	76,988	107,483
Revolving credit facility	179,000	60,000
Current portion of long-term debt, net	34,125	29,961
Total current liabilities	846,595	752,800
Long-term debt, net	2,386,004	2,591,981
Note payable - related party	41,447	39,706
Total long-term liabilities	2,564,670	2,837,613
Commitments and contingencies (Notes 5 and 21)
Redeemable non-controlling interests	41,293	24,949
Stockholders’ equity:
Preferred stock, $0.01 par value, 2,000 shares authorized; none issued at both December 31, 2023 and 2022	0	0
Additional paid-in capital	539,240	691,629
Stockholders' accumulated deficit	(490,176)	(406,183)
Accumulated other comprehensive (loss) income	(32,349)	9,939
Total Amneal Pharmaceuticals, Inc. stockholders' equity	19,781	298,421
Non-controlling interests	230	(114,442)
Total stockholders' equity	20,011	183,979
Total liabilities and stockholders' equity	3,472,569	3,799,341
Common Class A
Stockholders’ equity:
Common stock	3,066	1,514
Common Class B
Stockholders’ equity:
Common stock	0	1,522
Nonrelated Party
Current assets:
Trade accounts receivable, net	613,732	741,791
Operating lease right-of-use assets	30,329	38,211
Financing lease right of use assets	59,280	63,424
Current liabilities:
Accounts payable and accrued expenses	534,662	538,199
Current portion of operating lease liabilities	9,207	8,321
Current portion of financing lease liabilities	2,467	3,488
Operating lease liabilities	24,095	32,126
Financing lease liabilities	58,566	60,769
Other long-term liabilities	29,995	87,468
Related Party
Current assets:
Trade accounts receivable, net	955	500
Operating lease right-of-use assets	12,954	17,910
Current liabilities:
Accounts payable and accrued expenses	7,321	2,479
Current portion of operating lease liabilities	2,825	2,869
Operating lease liabilities	12,787	15,914
Other long-term liabilities	$ 11,776	$ 9,649

About Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

CEO	Mr. Chirag K. Patel
WEBSITE	https://amneal.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	7600

Amneal Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Amneal Pharmaceuticals Inc? What does AMRX stand for in stocks?

AMRX is the stock ticker symbol of Amneal Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amneal Pharmaceuticals Inc (AMRX)?

As of Tue Apr 16 2024, market cap of Amneal Pharmaceuticals Inc is 835.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMRX stock?

You can check AMRX's fair value in chart for subscribers.

What is the fair value of AMRX stock?

You can check AMRX's fair value in chart for subscribers. The fair value of Amneal Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amneal Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amneal Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMRX is over valued or under valued. Whether Amneal Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amneal Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMRX.

What is Amneal Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, AMRX's PE ratio (Price to Earnings) is -10.54 and Price to Sales (PS) ratio is 0.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMRX PE ratio will change depending on the future growth rate expectations of investors.